Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 2/20 | 0.48 |
| ▸ | PPM1B | O75688 | 2/20 | 0.48 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.48 |
| ▸ | TFPI2 | P48307 | 2/20 | 0.48 |
| ▸ | PPP5C | P53041 | 2/20 | 0.48 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | THPO | P40225 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21987140 | 1.00 | TP53 (0.48) | TP53LMNARAB9ASMN1; SMN2KDM4E | |
| SCHEMBL9602259 | 0.88 | TP53 (0.44) | TP53LMNARAB9ASMN1; SMN2KDM4E | |
| SCHEMBL1664815 | 0.71 | TP53 (0.33) | TP53LMNARAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5486329 | 0.69 | — | — | |
| SCHEMBL125505 | 0.69 | KDM4E (0.31) | TP53LMNARAB9ASMN1; SMN2KDM4E | |
| SCHEMBL14187990 | 0.68 | KDM4E (0.38) | TP53LMNARAB9ASMN1; SMN2KDM4E | |
| SCHEMBL21999910 | 0.68 | KDM4E (0.53) | TP53LMNARAB9ASMN1; SMN2KDM4E | |
| SCHEMBL910480 | 0.68 | KDM4E (0.53) | TP53LMNARAB9ASMN1; SMN2KDM4E | |
| SCHEMBL112827 | 0.68 | KDM4E (0.53) | TP53LMNARAB9ASMN1; SMN2KDM4E | |
| SCHEMBL19107418 | 0.68 | KDM4E (0.53) | TP53LMNARAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132106-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | CELLORAM, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4719369-A2 | INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING | Celloram, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12570603-B2 | FABP4/5 inhibitors, methods of use and methods of making | CELLORAM INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12514853-B2 | Therapeutic dendrimer | STARPHARMA PTY LTD. (AU) | 2026-01-06 | — | — | US | disclosed |
| CN-113056469-B | Therapeutic dendrimers | 星法马私人有限公司 | 2025-05-23 | — | — | CN | disclosed |
| WO-2024254161-A2 | INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING | CELLORAM INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-4402132-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | Celloram, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2023043803-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20220023290-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2022-01-27 | — | — | US | disclosed |
| EP-3883934-A1 | THERAPEUTIC DENDRIMER | Starpharma Pty Limited (AU) | 2021-09-29 | — | — | EP | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| EP-0309544-B1 | PSYCHOTROPIC BICYCLIC IMIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-02-10 | — | — | EP | disclosed |
| EP-0309544-A1 | PSYCHOTROPIC BICYCLIC IMIDES. | AMERICAN HOME PROD (US) | 1989-04-05 | — | — | EP | disclosed |
| WO-1988007530-A1 | PSYCHOTROPIC BICYCLIC IMIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-10-06 | — | — | WO | disclosed |
| US-4748240-A | Psychotropic bicyclic imides | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-05-31 | — | — | US | disclosed |
| US-4216215-A | 7[(Furanyl-2-acetamido)-2-acetamido]cephalosporin derivatives | PFIZER INC. (US) | 1980-08-05 | — | — | US | disclosed |
| US-4137312-A | Epoxy substituted cephalosporin derivatives | PFIZER INC. (US) | 1979-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023290-A1 | THERAPEUTIC DENDRIMER | DCK, PAICS, DCLRE1A | TP53 43/4885LMNA 753/4885RAB9A 1776/4885 |
| US-12570603-B2 | FABP4/5 inhibitors, methods of use and methods of making | FABP5, FABP1, FABP4 | TP53 1153/4885LMNA 2630/4885RAB9A 892/4885 |
| US-20260132106-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | FABP5, FABP4, FABP1 | TP53 1716/4885LMNA 2177/4885RAB9A 1822/4885 |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | TP53 513/4885LMNA 3136/4885RAB9A 2841/4885 |
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | FABP5, FABP1, FABP4 | TP53 746/4885LMNA 2368/4885RAB9A 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.